tiprankstipranks
Trending News
More News >
Avita Medical (RCEL)
NASDAQ:RCEL
US Market

Avita Medical (RCEL) Stock Forecast & Price Target

Compare
381 Followers
See the Price Targets and Ratings of:

RCEL Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Avita
Medical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RCEL Stock 12 Month Forecast

Average Price Target

$15.17
▲(149.92%Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Avita Medical in the last 3 months. The average price target is $15.17 with a high forecast of $19.00 and a low forecast of $12.50. The average price target represents a 149.92% change from the last price of $6.07.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","13":"$13","20":"$20","9.5":"$9.5","16.5":"$16.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,9.5,13,16.5,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Aug<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.34,10.083076923076923,10.826153846153845,11.569230769230769,12.312307692307693,13.055384615384614,13.798461538461538,14.541538461538462,15.284615384615385,16.027692307692305,16.770769230769233,17.513846153846153,18.256923076923076,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.34,9.788461538461538,10.236923076923077,10.685384615384615,11.133846153846154,11.582307692307692,12.03076923076923,12.47923076923077,12.927692307692308,13.376153846153846,13.824615384615385,14.273076923076923,14.721538461538461,{"y":15.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.34,9.583076923076923,9.826153846153845,10.069230769230769,10.312307692307693,10.555384615384614,10.798461538461538,11.041538461538462,11.284615384615385,11.527692307692307,11.77076923076923,12.013846153846153,12.256923076923076,{"y":12.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.58,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.06,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.55,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.65,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.72,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$19.00Average Price Target$15.17Lowest Price Target$12.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
$12.5
Buy
105.93%
Upside
Reiterated
05/14/25
Avita Medical's Strategic Expansion and Product Launches Justify Buy Rating
Lake Street Analyst forecast on RCEL
Brooks O'NeilLake Street
Lake Street
$14
Buy
130.64%
Upside
Reiterated
05/09/25
Avita Medical (RCEL) Gets a Buy from Lake Street
Cantor Fitzgerald Analyst forecast on RCEL
Ross OsbornCantor Fitzgerald
Cantor Fitzgerald
$19
Buy
213.01%
Upside
Reiterated
05/09/25
Cantor Fitzgerald Says Buy Avita Medical Ltd. (RCEL) on Weakness Following Q1 ResultsCantor Fitzgerald Says Buy Avita Medical Ltd. (RCEL) on Weakness Following Q1 Results
D. Boral Capital Analyst forecast on RCEL
Jason KolbertD. Boral Capital
D. Boral Capital
$25$22
Buy
262.44%
Upside
Reiterated
02/20/25
Avita Medical price target lowered to $22 from $25 at D. Boral CapitalAvita Medical price target lowered to $22 from $25 at D. Boral Capital
Piper Sandler Analyst forecast on RCEL
Matthew O'BrienPiper Sandler
Piper Sandler
$12$11
Hold
81.22%
Upside
Reiterated
02/14/25
Piper Sandler Remains a Hold on Avita Medical (RCEL)
BTIG
Hold
Reiterated
02/13/25
Analysts Conflicted on These Healthcare Names: Cochlear Limited (Other OTC: CHEOF) and Avita Medical (NASDAQ: RCEL)
Bank of America Securities Analyst forecast on RCEL
Lyanne HarrisonBank of America Securities
Bank of America Securities
Buy
Reiterated
08/09/24
Avita Medical (RCEL) Receives a Buy from Bank of America Securities
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TD Cowen
$12.5
Buy
105.93%
Upside
Reiterated
05/14/25
Avita Medical's Strategic Expansion and Product Launches Justify Buy Rating
Lake Street Analyst forecast on RCEL
Brooks O'NeilLake Street
Lake Street
$14
Buy
130.64%
Upside
Reiterated
05/09/25
Avita Medical (RCEL) Gets a Buy from Lake Street
Cantor Fitzgerald Analyst forecast on RCEL
Ross OsbornCantor Fitzgerald
Cantor Fitzgerald
$19
Buy
213.01%
Upside
Reiterated
05/09/25
Cantor Fitzgerald Says Buy Avita Medical Ltd. (RCEL) on Weakness Following Q1 ResultsCantor Fitzgerald Says Buy Avita Medical Ltd. (RCEL) on Weakness Following Q1 Results
D. Boral Capital Analyst forecast on RCEL
Jason KolbertD. Boral Capital
D. Boral Capital
$25$22
Buy
262.44%
Upside
Reiterated
02/20/25
Avita Medical price target lowered to $22 from $25 at D. Boral CapitalAvita Medical price target lowered to $22 from $25 at D. Boral Capital
Piper Sandler Analyst forecast on RCEL
Matthew O'BrienPiper Sandler
Piper Sandler
$12$11
Hold
81.22%
Upside
Reiterated
02/14/25
Piper Sandler Remains a Hold on Avita Medical (RCEL)
BTIG
Hold
Reiterated
02/13/25
Analysts Conflicted on These Healthcare Names: Cochlear Limited (Other OTC: CHEOF) and Avita Medical (NASDAQ: RCEL)
Bank of America Securities Analyst forecast on RCEL
Lyanne HarrisonBank of America Securities
Bank of America Securities
Buy
Reiterated
08/09/24
Avita Medical (RCEL) Receives a Buy from Bank of America Securities
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Avita Medical

1 Month
xxx
Success Rate
10/23 ratings generated profit
43%
Average Return
-1.51%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 43.48% of your transactions generating a profit, with an average return of -1.51% per trade.
3 Months
xxx
Success Rate
9/23 ratings generated profit
39%
Average Return
-4.15%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 39.13% of your transactions generating a profit, with an average return of -4.15% per trade.
1 Year
Success Rate
3/16 ratings generated profit
19%
Average Return
-24.41%
reiterated a buy rating 15 days ago
Copying Josh Jennings's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -24.41% per trade.
2 Years
xxx
Success Rate
1/16 ratings generated profit
6%
Average Return
-38.34%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 6.25% of your transactions generating a profit, with an average return of -38.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RCEL Analyst Recommendation Trends

Rating
Dec 24
Jan 25
Feb 25
Mar 25
May 25
Strong Buy
10
6
8
7
10
Buy
3
4
4
3
1
Hold
3
3
4
4
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
13
16
14
13
In the current month, RCEL has received 11 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. RCEL average Analyst price target in the past 3 months is 15.17.
Each month's total comprises the sum of three months' worth of ratings.

RCEL Financial Forecast

RCEL Earnings Forecast

Next quarter’s earnings estimate for RCEL is -$0.25 with a range of -$0.31 to -$0.16. The previous quarter’s EPS was -$0.53. RCEL beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.24% of the time in the same period. In the last calendar year RCEL has Preformed in-line its overall industry.
Next quarter’s earnings estimate for RCEL is -$0.25 with a range of -$0.31 to -$0.16. The previous quarter’s EPS was -$0.53. RCEL beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.24% of the time in the same period. In the last calendar year RCEL has Preformed in-line its overall industry.

RCEL Sales Forecast

Next quarter’s sales forecast for RCEL is $22.51M with a range of $21.60M to $23.35M. The previous quarter’s sales results were $18.51M. RCEL beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.66% of the time in the same period. In the last calendar year RCEL has Preformed in-line its overall industry.
Next quarter’s sales forecast for RCEL is $22.51M with a range of $21.60M to $23.35M. The previous quarter’s sales results were $18.51M. RCEL beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.66% of the time in the same period. In the last calendar year RCEL has Preformed in-line its overall industry.

RCEL Stock Forecast FAQ

What is RCEL’s average 12-month price target, according to analysts?
Based on analyst ratings, Avita Medical’s 12-month average price target is 15.17.
    What is RCEL’s upside potential, based on the analysts’ average price target?
    Avita Medical has 149.92% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RCEL a Buy, Sell or Hold?
          Avita Medical has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Avita Medical’s price target?
            The average price target for Avita Medical is 15.17. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $19.00 ,the lowest forecast is $12.50. The average price target represents 149.92% Increase from the current price of $6.07.
              What do analysts say about Avita Medical?
              Avita Medical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of RCEL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis